SCHEMBL5652992

SCHEMBL5652992

Cc1c(Cc2c(F)cccc2Cl)c(=O)oc2cc(O)ccc12

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD17B3 P37058 6/20 0.62
KDM4E B2RXH2 3/20 0.62
GLA P06280 3/20 0.62
GAA P10253 3/20 0.62
ERAP1 Q9NZ08 2/20 0.62
NPSR1 Q6W5P4 1/20 0.62
TP53 P04637 3/20 0.55
MAPT P10636 3/20 0.55
ALDH1A1 P00352 2/20 0.53
HPGD P15428 2/20 0.53
CASP1 P29466 2/20 0.53
CASP7 P55210 2/20 0.53
HSD17B10 Q99714 2/20 0.53
TSHR P16473 1/20 0.53
NQO1 P15559 1/20 0.52
ESR1 P03372 2/20 0.51
ESR2 Q92731 2/20 0.51
PKM P14618 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5646958 0.92 HSD17B3 (0.69) HSD17B3KDM4EGLAGAAERAP1
SCHEMBL15931622 0.86 HSD17B3 (0.56) HSD17B3KDM4EGLAGAAERAP1
SCHEMBL14305752 0.83 ALDH1A1 (0.63) HSD17B3KDM4EGLAGAAERAP1
SCHEMBL14317882 0.79 HSD17B3 (0.76) HSD17B3KDM4EGLAGAAERAP1
SCHEMBL5648321 0.78 HSD17B3 (0.70) HSD17B3KDM4EGLAGAAERAP1
SCHEMBL35210722 0.77 HSD17B3 (0.59) HSD17B3KDM4EGLAGAAERAP1
SCHEMBL14246785 0.77 HSD17B3 (0.77) HSD17B3KDM4EGLAGAAERAP1
SCHEMBL5647264 0.77 HSD17B3 (0.77) HSD17B3KDM4EGLAGAAERAP1
SCHEMBL5649508 0.77 TP53 (0.53) HSD17B3KDM4EGLAGAAERAP1
SCHEMBL5647929 0.77 MAP2K1 (0.56) KDM4EGAAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7279470-B2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2007-10-09 US disclosed
CN-1326519-C Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2007-07-18 CN disclosed
US-7067517-B2 Use of compounds for decreasing activity of hormone-sensitive lipase NERO NORDISK A/S (DK) 2006-06-27 US disclosed
CN-1602191-A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2005-03-30 CN disclosed
EP-1458375-A2 COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL HSD17B3 56/4885KDM4E 3457/4885GLA 107/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL HSD17B3 33/4885KDM4E 3778/4885GLA 118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.